Terms: = Ovarian cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1 AND Treatment
6 results:
1. Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy.
Mysona D; Dorr K; Ward A; Shaver E; Rungruang B; Ghamande S
Gynecol Oncol; 2023 Jan; 168():114-118. PubMed ID: 36434945
[TBL] [Abstract] [Full Text] [Related]
2. A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in cancer Patients.
Stodtmann S; Nuthalapati S; Eckert D; Kasichayanula S; Joshi R; Bach BA; Mensing S; Menon R; Xiong H
J Clin Pharmacol; 2021 Sep; 61(9):1195-1205. PubMed ID: 33894017
[TBL] [Abstract] [Full Text] [Related]
3. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
[TBL] [Abstract] [Full Text] [Related]
4. [ovarian Ablation in Breast cancer Patients and the Possibility of Influencing treatment Side Effects].
Palácová M
Klin Onkol; 2016; 29 Suppl 3():S29-38. PubMed ID: 28118722
[TBL] [Abstract] [Full Text] [Related]
5. Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
Hubalek M; Brantner C; Marth C
Wien Med Wochenschr; 2010 Apr; 160(7-8):167-73. PubMed ID: 20473727
[TBL] [Abstract] [Full Text] [Related]
6. Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.
Hutson PR; Tutsch KD; Rago R; Arzoomanian R; Alberti D; Pomplun M; Church D; Marnocha R; Cheng AL; Kehrli N; Wilding G
Clin Cancer Res; 1998 Jun; 4(6):1429-36. PubMed ID: 9626459
[TBL] [Abstract] [Full Text] [Related]